Phase 1/2 Trial of AFTX-201 in BAG3-Associated Dilated Cardiomyopathy Initiated
Affinia Therapeutics has launched Phase 1/2 trial for AFTX-201 targeting BAG3-associated dilated cardiomyopathy.
Company
Pharmaceutical intelligence for Affinia Therapeutics with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.